Envoy Medical, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
COCH$7.10-0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
EXHIBIT INDEX
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Exhibit Number | Description | Schedule/ Form | File No. | Exhibit | Filing Date |
| 2.1 (+) | Business Combination Agreement, dated as of April 17, 2023, by and among Anzu Special Acquisition Corp I, Envoy Merger Sub, Inc. and Envoy Medical Corporation. | 8-K | 001-40133 | 2.1 | April 18, 2023 |
| 2.2 | Amendment No. 1 to the Business Combination Agreement, dated May 12, 2023, by and among Anzu Special Acquisition Corp I, Envoy Merger Sub, Inc. and Envoy Medical Corporation. | S-4 | 333-271920 | 2.2 | May 15, 2023 |
| 2.3 | Amendment No. 2 to the Business Combination Agreement, dated August 31, 2023, by and among Anzu Special Acquisition Corp I, Envoy Merger Sub, Inc. and Envoy Medical Corporation. | S-4/A | 333-271920 | 2.3 | September 1, 2023 |
| 3.1 | Second Amended and Restated Certificate of Incorporation of the Company. | 8-K | 001-40133 | 3.1 | October 5, 2023 |
| 3.2 | Amended and Restated Bylaws of the Company. | 8-K | 001-40133 | 3.2 | October 5, 2023 |
| 3.3 | Certificate of Designation of Series A Preferred Stock of the Company. | 8-K | 001-40133 | 3.3 | October 5, 2023 |
| 4.1 | Warrant Agreement, dated March 1, 2021, between Anzu Special Acquisition Corp I and Equiniti Trust Company, LLC (formerly known as American Stock Transfer & Trust Company, LLC), as Warrant Agent. | 8-K | 001-40133 | 10.1 | March 4, 2021 |
| 4.2 | Form of Shortfall Warrant. | S-1/A | 333-276590 | 4.2 | February 15, 2024 |
| 4.3 | Description of Securities. | 10-K | 001-40133 | 4.3 | April 1, 2024 |
| 4.4 (#) | Form of Private Warrant | ||||
| 10.1 | Amendment to Letter Agreement, dated September 29, 2023, by and among Anzu Special Acquisition Corp I, Anzu SPAC GP I LLC and Anzu’s officers and directors. | 8-K | 001-40133 | 10.2 | October 5, 2023 |
| 10.2 (+) | Amended and Restated Registration Rights Agreement, dated September 29, 2023, by and among Anzu Special Acquisition Corp I, Anzu SPAC GP I LLC and certain stockholders. | 8-K | 001-40133 | 10.3 | October 5, 2023 |
| 10.3 (*) | Envoy Medical, Inc. Equity Incentive Plan. | 8-K | 001-40133 | 10.22 | October 5, 2023 |
| 10.4 (*) | Envoy Medical, Inc. Employee Stock Purchase Plan. | 8-K | 001-40133 | 10.23 | October 5, 2023 |
| 10.5 (*) | Form of Envoy Medical, Inc. Indemnification Agreement. | 8-K | 001-40133 | 10.21 | October 5, 2023 |
| 10.6 | Forward Purchase Agreement, dated as of April 17, 2023. | 8-K | 001-40133 | 10.4 | April 18, 2023 |
| 10.7 (+) | Amendment No. 1 to Forward Purchase Agreement, dated as of May 25, 2023. | S-4/A | 333-271920 | 10.27 | June 30, 2023 |
| 10.8 | Amendment No. 2 to Forward Purchase Agreement, dated as of September 28, 2023. | 8-K | 001-40133 | 10.24 | October 5, 2023 |
| 10.9 (*) | Employment Agreement, dated October 16, 2023, between Envoy Medical Corporation and Brent T. Lucas. | 8-K | 001-40133 | 10.1 | October 20, 2023 |
| 10.10 (*) | Employment Agreement, dated August 15, 2023, between Envoy Medical Corporation and David R. Wells. | 10-Q | 001-40133 | 10.10 | November 17, 2023 |
| 10.11 (*) | Letter Agreement, dated February 14, 2024, between Envoy Medical Corporation and Charles R. Brynelsen. | 10-K | 001-40133 | 10.11 | April 1, 2024 |
| 10.12 (*) | Letter Agreement, dated February 14, 2024, between Envoy Medical Corporation and Susan Kantor. | 10-K | 001-40133 | 10.12 | April 1, 2024 |
| 10.13 (*) | Letter Agreement, dated February 14, 2024, between Envoy Medical Corporation and Mona Patel. | 10-K | 001-40133 | 10.13 | April 1, 2024 |
| 10.14 (*) | Letter Agreement, dated February 14, 2024, between Envoy Medical Corporation and Janis Smith-Gomez. | 10-K | 001-40133 | 10.14 | April 1, 2024 |
| 10.15 (*) | Form of Option Award Agreement. | 10-K | 001-40133 | 10.15 | April 1, 2024 |
| 10.16 | Promissory Note, dated February 27, 2024, between Envoy Medical, Inc. and GAT Funding, LLC | 10-Q | 001-40133 | 10.1 | May 15, 2024 |
| 10.17 | Amendment to Forward Stock Purchase Agreement, dated July 29, 2024, between Envoy Medical, Inc. and the Meteroa FPA Parties. | 8-K | 001-40133 | 10.1 | August 1, 2024 |
| 10.18 | Promissory Note, dated August 27, 2024, between Envoy Medical, Inc. and GAT Funding, LLC. | 10-Q | 001-40133 | 10.1 | November 14, 2024 |
| 10.19 | Conversion and Waiver Agreement, dated December 20, 2024, by and between Envoy Medical, Inc. and Anzu SPAC GP I LLC. | 8-K | 001-40133 | 10.1 | December 20, 2024 |
| 10.20 | Amendment No. 1 to Common Stock Purchase Warrant, issued by Envoy Medical, Inc. to the Meteora Parties. | 8-K | 001-40133 | 10.1 | June 25, 2024 |
| 10.21 | Amendment No. 2 to Common Stock Purchase Warrant, issued by Envoy Medical, Inc. to the Meteora Parties. | 8-K | 001-40133 | 10.1 | December 23, 2024 |
| 10.22 | At The Market Offering Agreement dated as of January 17, 2025, between Envoy Medical, Inc and Roth Capital Partners, LLC | 8-K | 001-40133 | 10.1 | January 17, 2025 |
| 10.23 (#) | Building Lease dated as of May 20, 2016, between Envoy Medical Corporation and Taylor Corporation, as amended. | ||||
| 10.24 (#) | Servies Agreement dated as of January 1, 2022, between Envoy Medical Corporation and Taylor Technology Services, Inc. | ||||
| 16.1 | Letter of WithumSmith+Brown, PC to the Securities and Exchange Commission, dated October 24, 2023. | 8-K | 001-40133 | 16.1 | October 24, 2023 |
| 19.1 | Envoy Medical, Inc. Policy on Inside Information and Insider Trading. | 10-K | 001-40133 | 19.1 | April 1, 2024 |
| 21.1 (#) | List of Subsidiaries. | ||||
| 23.1 (#) | Consent of Independent Registered Public Accounting Firm | ||||
| 24.1 (#) | Power of Attorney (included on signature pages herein). | ||||
| 31.1 (#) | Certification of the Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a). | ||||
| 31.2 (#) | Certification of the Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a). | ||||
| 32.1 (#) | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.2 (#) | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 97 | Envoy Medical, Inc. Policy for the Recoupment of Erroneously Awarded Compensation. | 10-K | 001-40133 | 97.1 | April 1, 2024 |
| 101.INS(#) | Inline XBRL Instance Document. | ||||
| 101.SCH(#) | Inline XBRL Taxonomy Extension Schema Document. | ||||
| 101.CAL(#) | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | ||||
| 101.DEF(#) | Inline XBRL Taxonomy Extension Definition Linkbase Document. | ||||
| 101.LAB(#) | Inline XBRL Taxonomy Extension Label Linkbase Document. | ||||
| 101.PRE(#) | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | ||||
| 104(#) | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | ||||
| (*) | Indicates a management contract or compensatory plan. |
|---|
| (#) | Filed herewith. |
|---|
| (+) | Certain schedules and exhibits to this Exhibit have been omitted pursuant to Item 601(a)(5) or Item 601(b)(10)(iv), as applicable, of Regulation S-K. The registrant agrees to furnish supplemental copies of all omitted exhibits and schedules to the Securities and Exchange Commission upon its request. |
|---|
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| March 28, 2025 | ENVOY MEDICAL, INC. | |
|---|---|---|
| /s/ Brent T. Lucas | ||
| Name: | Brent T. Lucas | |
| Title: | Chief Executive Officer |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.